RxDoctor Payments Data

Catherine Bennet

Internal Medicine · Chevy Chase, MDNPI 1346543469

Payments from drug & device makers

$6,283in general payments, 2019–2025

Across 152 payments — averaging $41.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$924
  • Amgen$813
  • Medtronic$750
  • E.r. Squibb & Sons, L.L.C.$438
  • Novo Nordisk$414
  • Boston Scientific$399
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$6,283100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,283 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$473,625
Medicare patients
925
Services billed
4,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban248$359,844
XareltoRivaroxaban53$63,580
Repatha SureclickEvolocumab51$60,435
JardianceEmpagliflozin18$20,724
EntrestoSacubitril/Valsartan14$16,989
Praluent PenAlirocumab18$14,589
Rosuvastatin Calcium247$5,794
Metoprolol Succinate287$5,233
Atorvastatin Calcium224$3,813
Ezetimibe79$2,717
Losartan Potassium182$1,668
Amlodipine Besylate214$1,627
Flecainide Acetate26$1,556
Olmesartan Medoxomil86$1,505
Diltiazem 24hr Er (Cd)Diltiazem Hcl37$1,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$316$359,844248 claims
Johnson & JohnsonXarelto$209$63,58053 claims
Boehringer IngelheimJardiance$42$20,72418 claims
NovartisEntresto$283$16,98914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →